Last updated on: 24/08/2020
Name of organisation
1) Department/Research groupCenter for Public Health Research
2) Organisation/affiliationUniversity of Milan Bicocca
Short Name in the inventoryCESP
Administrative Contact
Title Ms
Last name Roberta
First name Mariani
Address line 1Via Cadore 48
Address line 2
Address line 3
CityMonza
Postcode20090
CountryItaly
Phone number (incl. country code)39-(0)39-2333097
Alternative phone number
Fax number (incl. country code)
Scientific Contact
Title Professor
Last name Mazzaglia
First name Giampiero
Address line 1Via Cadore 48
Address line 2
Address line 3
CityMonza
Postcode20090
CountryItaly
Phone number (incl. country code)39-(0)39-2332678
Alternative phone number39-(0)347-6764123
Fax number (incl. country code)
2. Description
The Research Centre on Public Health (CESP) of the University of Milano-Bicocca supports and encourages research in order to promote and safeguard public health.
CESP has been running patients' registries since the mid 80's, including WHO's MONICA. More recently CESP has developed tools to link different health and healthcare archives using probabilistic record linkage. Currently >15 researchers operate within CESP, with exhaustive background and expertise in Medicine, Pharmacy, Regulatory Sciences, Biotechnology, Chemistry, (Pharmaco)Epidemiology, Biostatistics and Medical Informatics. Members of CESP are involved in several pharmacoepi and PV pieces of research, including retrospective and prospective registries, retrospective safety studies based on administrative databases, as well as prospective post-authorization safety studies.
3. Category
University based
4. Available resources
In houseVia Contacts/Network
Biotechnology
Yes
No
5. Therapeutic/disease areas of research in drug safety/risk-benefit performed in the past 5 years
Cardiovascular diseases
Devices
Disorders of the central nervous system
Endocrine disorders
Eye disorders
Gastrointestinal tract
Immunological products and vaccines
Infectious diseases
Liver disease
Malignant disease
Musculoskeletal and joint diseases
Nutrition and blood
Renal impairment
Respiratory diseases
Skin disorders
rare diseases (haemophilia)
6. Design of drug safety/risk-benefit studies published in the past 5 years
Cohort Study
Drug Utilisation
Interventional Clinical Trial
Meta-Analysis
7. Experience in collecting data directly from individual patients/respondents
Number of Studies
Greater than 5
Number of patients/respondents involved in the study(ies)
Greater than 15000
8. Access to data collection resources
Capacity to conduct face-to-face interviews
Yes
In a clinic
Yes
In the community
Yes
Electronic data capture systems
No
Interactive voice response systems
No
Call centre
No
9. Experience in secondary research and meta-analysis
Yes
10. Work with existing data resources in the past 3 years
Name of data resourceNo. of studies
Hospital Discharge15
11. Registries established by centre
Disease RegistryMONICA, PAMELA, CAMUNI, etc...
Other Device Registries
12. Experience in collaboration in a study team
Principal Investigator
Collaborating Investigator
13. Current involvement in research networks
None
14. Interest in research opportunities which are funded
By pharmaceutical companies
By charities
By government
By research councils
By EU funding schemes
15. Interest in contract research only if free to publish results
Yes
16. Selected publications of the last 5 calendar years
ReferenceLink to web-publication
Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, Borghi C, Brignoli O, Caputi AP, Cricelli C, Mantovani LG. Adherence to antihypertensive medications and cardiovascular morbidity among newly-diagnosed hypertensive patients. Circulation 2009;120:1598-1605http://circ.ahajournals.org/content/120/16/1598.full.pdf+html
Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, Cortesi P, Jo H, Kavakli K, Lassila R, Morfini M, Négrier C, Rocino A, Schramm W, Serban M, Uscatescu MV, Windyga J, Zülfikar B, and Mantovani L. Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors. N Eng J Med 2011. 365:1684-92.
http://www.nejm.org/doi/pdf/10.1056/NEJMoa1104435
Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, van Eickels M, Gebel M, Zell E, Turpie AG. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. ancet Haematol. 2016 Jan;3(1):e12-21. doi: 10.1016/S2352-3026(15)00257-4.https://www.sciencedirect.com/science/article/pii/S2352302615002574?via%3Dihub
Mazzaglia G, Straus SMJ, Arlett P, da Silva D, Janssen H, Raine J, Alteri E. Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs. Drug Saf. 2018 Feb;41(2):191-202. doi: 10.1007/s40264-017-0604-4.https://link.springer.com/article/10.1007%2Fs40264-017-0604-4
Corbalan R, Bassand JP, Illingworth L, Ambrosio G, Camm AJ, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators. Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry. JAMA Cardiol. 2019 May 8. doi: 10.1001/jamacardio.2018.4729.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2732488
